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Introduction: Postoperative acute kidney injury (AKI) is a frequently observed phenomenon after cardiac surgery
with cardio-pulmonary bypass (CPB); this severe complication is associated with adverse patient outcomes. There
are multiple mechanisms involved in AKI during cardiac surgery, including CPB-dependent hemolysis. An IV
infusion of sodium bicarbonate, which leads to urine alkalization, may play a role in preventing AKI. Recently,
several trials have investigated the effect of sodium bicarbonate and reported controversial results. The purpose of
this investigation was to investigate the following question. Under what circumstances can sodium bicarbonate
prevent postoperative AKI?
Methods: We analyzed data from 342 patients undergoing CPB surgery at the University Hospital Goettingen,
Germany. A total of 174 patients received a preemptive dose of sodium bicarbonate. Directly after the induction of
anesthesia, the continuous infusion of 0.15 mmol/kg body weight/h was started and continued until 2 pm on the
first postoperative day. Patients who were not treated with sodium bicarbonate formed the control group (n = 168).
To verify the AKI risk configuration of each group, we surveyed risk factors and determined the commonly used
clinical predictive score according to Thakar and colleagues. We recorded the concentration of free hemoglobin
(fhb) to estimate the amount of CPB-dependent hemolysis. The definition of AKI was acquired by applying the
AKI-network (AKIN) classification over the course of five postoperative days.
Results: Patients who received the sodium bicarbonate infusion showed a significantly lower incidence (35.6 vs.
50%) of AKI than that of patients who did not receive the infusion (p = 0.01). AKIN levels 2 and 3 were also more
frequent when sodium bicarbonate was not administered. Particularly, in the low-risk cohort (<3 Thakar points), the
incidence of AKI was significantly reduced (26 vs. 46%) when patients received sodium bicarbonate (p = 0.01),
whereas in the high-risk patients, no significant reduction was observed.
Conclusion: In this study, we observed that low-risk patients particularly benefited from the preventive treatment
with sodium bicarbonate. The incidence of AKI was significantly reduced in low-risk patients while there was no
statistically significant difference in the high-risk patient cohort.
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Postoperative acute kidney injury (AKI) is a frequently
observed phenomenon after cardiac surgery with cardio-
pulmonary bypass (CPB); this severe complication is asso-
ciated with adverse patient outcomes and has extensive
medical and economic consequences [1]. It is one of the
most common organ dysfunctions encountered in inten-
sive care medicine [2], and cardiac surgery is among its
most frequent causes [3]. AKI requiring renal replacement
therapy (RRT) has been reported in 5% of patients after
cardiac surgery; 8 to 15% present increased serum creatin-
ine of >1.0 mg/dl; and a discrete increase of creatinine of
25% relative to the baseline is found in 50% of patients [4].
Surgery with CPB increases the postoperative mortality by
2 to 8%; in the event of AKI, however, the mortality rate
increases exponentially, reaching up to 60% for patients
who require RRT [5,6].
There are multiple mechanisms involved in kidney
injury during cardiac surgery, including ischemia re-
perfusion injury, perioperative hemodynamic instability,
impaired renal blood flow, CPB-induced activation of
inflammatory pathways, generation of reactive oxygen
species and hemolysis [4,7]. Hemolysis during CPB is in-
duced by the mechanical destruction of erythrocytes due
to contact with the surfaces of the bypass circuit, high
blood flow and pressure conditions, and cardiotomy suc-
tion [4,8]. Consequently, the released free hemoglobin
(fhb) passes through the glomerulus after it exceeds the
binding capacity of haptoglobin [9]. The fhb then causes
tubular obstruction with met-hemoglobin casts and
tubular cell necrosis. Furthermore, free iron is released,
which is involved in the generation of reactive oxygen
species [4].
The administration of sodium bicarbonate, which re-
sults in urinary alkalization, may thus help to prevent
hemoglobin-associated pigment nephropathy. Urinary
alkalization prevents tubular obstruction due to cast for-
mation by reducing the conversion of hemoglobin to
met-hemoglobin. It also reduces the endocytotic uptake
of hemoglobin, thereby protecting against cell necrosis
of the proximal tube. Furthermore, urinary alkalization
protects from oxidant injury by shifting the equilibrium
of the Haber-Weiss reaction towards a lower production
of hydroxyl radicals and therefore limiting the produc-
tion of further free radicals and other reactive species
(for example, peroxynitrite and free-iron-mediated hy-
droxyl radical formation) [4,10]. Additionally, one might
presume that in alkaline pH the physiological scavenging
of free radicals is promoted; a direct scavenging ability
of bicarbonate itself has also been suggested [11].
Recently, several trials and meta-analyses have investi-
gated the clinical effects of sodium bicarbonate, yielding
controversial results [7,12-18]. To investigate the circum-
stances under which sodium bicarbonate can preventpostoperative AKI in our patient cohort, we determined
the influence of a perioperative intravenous (IV) infusion
of sodium bicarbonate on the incidence of AKI after car-
diac surgery.
Methods
We analyzed data from 342 patients of the University
Hospital Goettingen, Germany. Based on a pilot study
[12] and a position paper of the Renal Failure working
group of the collaborative group, Cardiothoracic Intensive
Care of the German Society of Anesthesiology and Inten-
sive Care Medicine (DGAI) and of the German Society of
Thoracic and Cardiovascular Surgery (DGTHG) [19], a
new standard operating procedure was implemented in
our department that recommended a perioperative IV in-
fusion of sodium bicarbonate. This change occurred while
we carried out a prospective large observational study that
recorded predictive factors for AKI after CPB and moni-
tored the incidence of AKI over a five-day period follow-
ing surgery (data not yet published). This observational
study was approved by the local ethics committee of the
University of Goettingen (number 21/6/09), and we used a
subset of this study to analyze the influence of sodium
bicarbonate.
All patients undergoing cardiac surgery with CPB were in-
cluded in the study through their participation in the afore-
mentioned observational clinical trial with informed patient
consent. We excluded patients with incomplete datasets, pa-
tients who were younger than 18 years of age, patients with
chronic renal failure requiring RRT before surgery, patients
for whom cardiac surgery was planned to not include CPB,
heart-transplant patients, and patients with preoperative
extra-corporal membrane-oxygenation (ECMO).
To analyze the influence of sodium bicarbonate, we
divided the study cohort into two groups. Group 2
(called the NaHCO3 group) received a preemptive dose
of sodium bicarbonate in accordance with the aforemen-
tioned new standard operating procedure. While imple-
menting the new standard administration of sodium
bicarbonate at the end of the aforementioned observa-
tional trial, 225 patients, all of whom received sodium
bicarbonate, were included in the observational study
and formed the NaHCO3 group of this study. Directly
after the induction of anesthesia, a continuous IV infu-
sion of 0.15 mmol/kg body weight/h was started and
continued until 2 pm on the first postoperative day,
modified from the procedure reported in the pilot study
of Haase and colleagues [12].
Group 1 was assigned as the control group and in-
cluded the final 225 patients (in accordance with the size
of group 2) who were enrolled in the observational study
before the new standard operating procedure was imple-
mented and who consequently did not receive sodium
bicarbonate.
Wetz et al. Critical Care  (2015) 19:183 Page 3 of 10To verify the AKI risk configuration of both groups,
we surveyed individual patients according to various risk
factors and determined the commonly used clinical pre-
dictive score according to Thakar and colleagues [6],
which demonstrated an acceptable ability to predict the
risk of AKI [20,21]. The following biometrical character-
istics, comorbidities and surgical factors were recorded:
gender, age, left-ventricular ejection fraction (EF), congest-
ive heart failure (CHF)/NYHA-classification, chronic ob-
structive pulmonary disease (COPD), insulin-dependent
diabetes mellitus (IDDM), the use of a preoperative intra-
aortic balloon pump (IABP), and the preoperative concen-
tration of serum creatinine.
We documented the surgical procedures as coronary
artery bypass grafting (CABG) only, valve surgery only,
combined CABG-valve surgery, or other surgeries (for
example, myectomy, aortic arch surgery, and CABG with
maze procedures and CPB); primary surgery or repeat
surgery, and elective or emergency surgery. We also do-
cumented the duration of CPB and the aortic cross-
clamping (ACC) time as surgical factors. Additionally, we
recorded the baseline concentration of fhb and the con-
centration of fhb after the arrest of CPB as the assumed
nephrotoxic agent to estimate the level of CPB-dependent
hemolysis.
Postoperatively, the definition and evolution of AKI
was evaluated by applying the Acute Kidney Injury Net-
work (AKIN) classification [22]. Daily AKIN levels were
determined by the diuresis rate and the serum creatinine
concentration. We considered the maximum AKIN level
achieved by each patient during the observed time period
from the day of surgery until the fifth postoperative day.
Consequently, patients were categorized into groups with-
out AKI (AKIN 0) and with AKI (AKIN 1 to 3). Addition-
ally, the serum creatinine concentration on day 10 after
surgery, the length of stay (LOS) in hospital, length of stay
in an intensive care unit (LOS-ICU) and in-hospital mor-
tality were recorded as outcome parameters. Further, fluid
balances up to the first postoperative day were analyzed.
Risk stratification for AKI and the comparability be-
tween the NaHCO3 group and control group were accom-
plished and ensured via statistical analysis and included
testing distributions with the Kolmogorov-Smirnov test
and applying univariate analysis with the Mann-Whitney
U-test and the chi-squared (chi2) test, as well as logistic
regression. Because the fhb concentration (as a risk factor)
was higher in the control group than in the NaHCO3
group, we performed a multivariate logistic regression
analysis (using backward selection, entry criteria P <0.05,
and exit criteria P >0.1) with the two factors fhb and
sodium bicarbonate to verify the independent influence of
sodium bicarbonate on the incidence of AKI. Receiver
operating characteristic (ROC) analysis was used to deter-
mine a cutoff point for the Thakar score to discriminatebetween patients at low risk and high risk of developing
AKI (maximizing the sensitivity and specificity using the
Youden index).
To analyze the effect of sodium bicarbonate, the inci-
dence of AKI (according to the AKIN classification) was
compared between the control group and the NaHCO3
group using the chi2 test. We also analyzed the effect of
sodium bicarbonate in subgroups, categorized by the
surgery procedure and low or high AKI risk (Thakar
score). Non-normally distributed data were expressed as
median and IQR, and normally distributed data as mean
and standard deviation. A P-value <0.05 was considered
statistically significant. Statistical analyses were carried
out using Statistica (Version 10, 1984–2011, StatSoft Inc.,
Tulsa, OK, USA) and MedCalc (Version 12.4.0.0. for Win-
dows XP/VISTA/7/8, MedCalc Software, Ostend, Belgium).
Results
After exclusions due to incomplete data, 342 patients
remained in the analysis. The study population consisted
of 74% male patients with a median age of 70 years.
They mostly underwent CABG surgery, followed by valve
surgery, combined valve and CABG surgery and other
types of surgery with CPB. Emergency or previous surger-
ies were performed in 3% of patients. The incidence of the
preoperative risk factors EF <35%, COPD and IDDM were
10, 14 and 16%, respectively. CHF was recorded in more
than 40% of the patients. Preoperative IABP was used in
one patient. The median serum creatinine was 0.96 mg/dl,
whereas serum creatinine >1.2 mg/dl was recorded in 23%
of the patients. Individual predictive score points accord-
ing to Thakar et al. ranged from 0 to 10 points [6], with a
median score of 2 points, and 18% of the patients pre-
sented with 0 Thakar points (and were accordingly as-
signed as very low risk for AKI requiring RRT). The
median CPB time was 115 minutes, and the median ACC
time was 73 minutes. The baseline concentration of fhb
was 9 mg/dl, which increased to a median of 50 mg/dl
after ending CPB (Tables 1 and 2).
Group 1 consisted of 168 patients who did not receive
sodium bicarbonate therapy, and group 2 consisted of
174 patients who received an IV infusion of sodium
bicarbonate.
Statistical analysis of each risk factor had the following
distributions in the control and NaHCO3 groups: univari-
ate analysis of gender, age, COPD, IDDM, EF <35%, CHF
and IABP revealed no significant differences in distribu-
tions between the cohort of patients who received sodium
bicarbonate and the cohort who did not (P-values are also
presented in Table 1). Neither were significant differ-
ences in distributions observed in univariate analyses of
preoperative serum creatinine concentration, surgery type,
emergency or repeat surgery or CPB time. Individual score
points were also equally distributed. However, patients in
Table 1 Descriptive statistics of the study cohort and results of the univariate analysis for each risk factor
All Control group NaHCO3 group
Number % Number % Number % P-value
Biometric data
Female 90 26.32 43 25.6 47 27.01 0.86
Male 252 73.68 125 74.4 127 72.99 0.86
Comorbidities
IABP 1 0.29 0 0 1 0.57 0.98
Ejection fraction <35% 35 10.23 20 11.9 15 8.62 0.41
IDDM 49 14.33 23 13.69 26 14.94 0.86
COPD 56 16.37 25 14.88 31 17.82 0.56
Creatinine >1.2 mg/dl 79 23.1 40 23.81 39 22.41 0.86
Congestive heart failure 145 42.4 68 40.48 77 44.25 0.55
Surgery characteristics
CABG 182 53.22 83 49.40 99 56.90 0.27
Valve 53 15.5 31 18.45 22 12.64 0.27
CABG + valve 40 11.7 23 13.69 17 9.77 0.43
Other surgery 67 19.59 31 18.45 36 20.69 0.63
Repeat surgery 9 2.63 2 1.19 7 4.02 0.19
Emergency surgery 9 2.63 5 2.98 4 2.30 0.96
Numbers and percentages for biometric data, comorbidities, and surgery characteristics are presented. Statistical analysis was performed using the chi2 test. IABP,
intra-aortic balloon pump; IDDM, insulin-dependent diabetes mellitus; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass graft.
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concentration of fhb (55 versus 45 mg/dl) and a five-
minute longer ACC time than that of patients who re-
ceived sodium bicarbonate treatment (Tables 1 and 2).
AKI was identified in 42.7% of the 342 patients (Table 3).
In the group who received preemptive treatment with
sodium bicarbonate, the AKI incidence was 35.6%, com-
pared to 50% in the group without treatment, indicating
that patients who received sodium bicarbonate showed a
significantly reduced incidence of AKI compared with that
of patients who were not administered sodium bicar-
bonate (P = 0.01). In particular, AKIN levels 2 and 3 wereTable 2 Distributions of non-categorical data
Control group
Median IQR Range
Age, years 70 62, 74 34 to 84
Creatinine, mg/dl 0.96 0.81, 1.18 0.5 to 2.1
Score points 2 1.0, 3.5 0 to 10
ACC time, minutes 74.5 61.5, 97.5 17 to 214
CPB time, minutes 116 94, 147.5 42 to 310
fhb at baseline, mg/dl 9 8.0, 11.0 4.0 to 93
fhb after CPB, mg/dl 55 40,73 7.0 to 187
Distributions of non-categorical data, which are expressed as median, IQR, and rang
concentration of serum creatinine, and concentration of free hemoglobin (fhb) at b
Mann-Whitney U-test was used to evaluate the distribution of score points. The fhb
aortic cross-clamping (ACC) time was significantly shorter.identified more frequently in the group without sodium
bicarbonate treatment, whereas the incidence of AKIN
level 1 remained unchanged (Figure 1). We found that
62% of the patients classified as AKIN 1 still had serum
creatinine concentrations >1.2 mg/dl on day 10 after sur-
gery. However, there was no significant difference between
patients with or without sodium bicarbonate treatment
(P = 0.840). We also found no significant difference in the
quotient of the day-10 value to the baseline concentration
between both groups (P = 0.370).
Comparing the in-hospital mortality rate and LOS
(for both hospitalization and intensive care) revealedNaHCO3 group
Median IQR Range P-value
70 60, 74 42 to 88 0.64
0.97 0.81, 1.13 0.54 to 4.57 0.26
2 1.0, 4.0 0 to 10 0.86
69.5 52, 91 29 to210 0.03
112.5 89, 138 45 to 313 0.06
9 8.0, 11.0 5.0 to 55 0.18
45 34, 62 11 to 130 0.001
e. Tests of the distributions of age, cardiopulmonary bypass (CPB) time,
aseline and at the end of CPB were performed by logistic regression. The
concentration after CPB was significantly lower in the NaHCO3 group, and the
Table 3 Acute Kidney Injury Network (AKIN) classification
in the total cohort (342 patients), in the control group
and in the NaHCO3 group
All Control group NaHCO3 group
Number % Number % Number %
AKIN 0 196 57.31 84 50.00 112 64.37
AKIN >0 146 42.69 84 50.00 62 35.63
AKIN 1 105 30.70 52 30.95 53 30.46
AKIN 2 20 5.85 15 8.93 5 2.87
AKIN 3 21 6.14 17 10.12 4 2.30
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sodium bicarbonate and those without treatment. The
median LOS was 11 days, and the mortality rate was 2.6%
(Table 4).
The mean fluid balance up to the first postoperative
day was significantly higher in the group of patients who
received sodium bicarbonate than in the control group
(2806 ± 1607 ml versus 1517 ± 1622 ml, P <0.0001). How-
ever, there was no difference between patients with and
without AKI (P = 0.244) or high-risk and low-risk patients
(P = 0.319).
Multivariate analysis of the two factors (sodium bicar-
bonate and fhb after finishing CPB) demonstrated that
receiving sodium bicarbonate has not only a significant
but also an independent effect on the prevention of AKI.
The absence of sodium bicarbonate contributed to
AKI, with an odds ratio of 1.57 (95% CI 1.0009, 4.4494)
(Table 5).
To analyze the effect of sodium bicarbonate in low-
risk and high-risk AKI patients, we performed a ROC
analysis to subdivide the cohort. The cutoff point of the
Thakar score was set at 3 points to discriminate between
the low-risk and high-risk patients (Figure 2). Accord-








AKIN 0 AKIN 1 AKIN 2
Figure 1 Acute Kidney Injury Network (AKIN) levels.patients with a score ≥3 points were assigned as high-
risk patients, and patients with scores <3 points were
defined as low-risk patients (n = 181). In the low-risk
cohort, the AKI incidence was significantly lower (26
versus 46%) when patients received sodium bicarbonate;
not receiving the treatment contributed to AKI with an
OR of 2.34 (95% CI 1.25, 4.36). In the high-risk cohort,
the AKI incidence was lower in the NaHCO3 group than
in the control group (46 versus 55%), but the difference
was not significant (Table 6).
After categorizing the patient cohort by surgical pro-
cedure, we found that the AKI incidence in patients
undergoing CABG surgery was reduced significantly (52
versus 34%) when sodium bicarbonate was administered.
We also found that patients who underwent CABG sur-
gery had a lower median concentration of fhb compared
to patients who underwent other types of surgery. For
the other surgical procedures, no significant decrease in
the incidence of AKI was detected (Table 7).
Discussion
In this study, we analyzed the influence of perioperative
treatment with sodium bicarbonate IV on the incidence
of AKI after CPB. We observed that the incidence of
AKI was significantly lower in the group of patients who
received the sodium bicarbonate treatment: 50% inci-
dence of AKI (control group) versus 35.6% (NaHCO3
group). Apart from the fhb concentration and ACC time
(which can possibly be attributed to the slightly in-
creased number of combined CABG-valve operations in
the control group), none of the comorbidities, or biomet-
ric or surgical factors were significantly different between
the two groups. Although the fhb concentration was
slightly higher in the control group, an independent,
significant influence of sodium bicarbonate on AKI was
demonstrated. Accordingly, our results showed that theAKIN 3
control group
NaHCO3 group
Table 4 Length of hospital stay in days, length of intensive
care stay, and in-hospital mortality in the control group
and in the NaHCO3 group
Control group NaHCO3 group P-value
Length of stay, days,
median (IQR)
11 (8, 15) 11 (8, 15) 0.7834
Length of stay in ICU,
days, median (IQR)
2 (1, 4) 1 (1, 4) 0.1969
Mortality, number (%) 3 (1.79) 6 (3.45) 0.5050
The Mann-Whitney U-test and chi2 tests revealed no significant differences
between the two groups.
Figure 2 Receiver operating characteristic analysis.
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the postoperative AKI incidence after surgery with CPB in
our study population, especially in patients with a lower
preoperative risk of renal failure.
Preventive and therapeutic effects of sodium bicarbon-
ate have been under discussion for a long time, dating
back to the 1980s [23]. In the past, several studies have
been published about the preventive use of sodium bi-
carbonate in the context of contrast-induced nephropa-
thy [24]; however, in 2009, Haase and colleagues were
the first to publish a randomized, double-blind, placebo-
controlled trial examining cardiac surgery with CPB
[12]. Potential side effects of sodium bicarbonate include
increased plasma sodium concentrations and metabolic
alkalosis [12,14]. In the present study, patients who re-
ceived sodium bicarbonate had a significantly higher pH
level of 7.41 (IQR 7.38, 7.44), in contrast to 7.39 (IQR
7.36, 7.42) in the control group, on the day of surgery
and the first postoperative day (P <0.0001). No patient
developed a plasma sodium concentration >150 mmol/l;
marginal hypernatremia (>145 < 147 mmol/l) occurred
in two patients.
Our results consequently support the hypothesis of
Haase et al. 2009, indicating that sodium bicarbonate is
an effective, simple, practical, and inexpensive therapeutic
measure to prevent the nephrotoxic effects of CPB-
dependent hemolysis [4,12,25]. However, other published
trials have failed to reconfirm the results of the pilot study.
None of those trials except one found that a sodium bi-
carbonate infusion reduced AKI incidence after cardiac
surgery with CPB [7,12-18].
Based on the findings of the pilot study, the adminis-
tration of sodium bicarbonate was implemented in our
department of the University of Goettingen, Germany.
We evaluated the effect of sodium bicarbonate infusionTable 5 Multivariate analysis
P-value Odds ratio 95% CI
Sodium bicarbonate 0.0496 1.5657 1.0009, 4.4494
Free hemoglobin 0.0001 1.0183 1.0089, 1.0277
Influence of the absence of sodium bicarbonate treatment and free hemoglobin
at the end of cardiopulmonary bypass on acute kidney injury.without randomization while the new standard operating
procedure was being established. After the implementa-
tion of this new standard operating procedure, all pa-
tients received sodium bicarbonate and therefore formed
the NaHCO3 group. As described above, the control
group included patients who underwent cardiac surgery
prior to the implementation of the standard operating
procedure and who therefore did not receive sodium bi-
carbonate. The data in the present study originated from
a large observational prospective study to evaluate AKI
risk after cardiac surgery, which represents high-quality
data recruitment. Despite the limitation that the treatment
was not randomized, this study analyzed the effects of
sodium bicarbonate on a large sample size of nearly 350
patients.
AKI was determined over five postoperative days using
the AKIN classification, which is an objective, compar-
able, and precise definition of AKI. In contrast to other
studies, we did not further apply AKI criteria nor record
the use of diuretic therapy. In our department, we pur-
sue a strategy that limits the use of diuretics. During sur-
gery, during the first 24 hours after surgery and during
the manifestation of oliguria to anuria, we refrained
from administering any diuretics because several studies,
including prospective randomized trials, have shown a
worsening of renal function due to early diuretic use in
cardiac surgical patients [26-28]. Even if diuretics were
administered, it can be assumed that they had no effect
on serum creatinine, allowing an accurate reflection of
the extent of AKI even under diuretic therapy. Because
the worse of the two criteria (urinary output and serum
Table 6 AKI incidence in the control group and the NaHCO3 group in low-risk and high-risk AKI patient
Low-risk (score points 0 to 2) Control group (n = 90) NaHCO3 group (n = 91)
Number % Number % P-value
AKIN 0 49 54.44 67 73.63 0.0113
AKIN >0 41 45.56 24 26.37
High-risk (score points 3 to 10) Control group (n = 78) NaHCO3 group (n = 83)
Number % Number % P-value
AKIN 0 35 44.87 45 54.22 0.3042
AKIN >0 43 55.13 38 45.78
The acute kidney injury (AKI) incidence was significantly lower in the low-risk cohort when patients received sodium bicarbonate.
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our trial), diuretics should not have an effect on the
AKIN classification.
The mean fluid balance up to the first postoperative
day was significantly higher in the group of patients who
received sodium bicarbonate than in the control group.
However, there were no differences in fluid balances be-
tween patients with and without AKI or high-risk and
low-risk patients. It is possible that dilution effects may
have influenced the results. A lower incidence of AKIN
1 in the sodium bicarbonate group, consistent with
lower serum creatinine concentrations, might partly be
explained by a dilution effect due to higher fluid bal-
ances. Second, higher fluid balances may have directly
contributed to the prevention of AKI. However, as there
were no differences in fluid balances between patients
with and without AKI, and high-risk and low-risk patients,
respectively, our results still indicate a direct preventive
effect of sodium bicarbonate on AKI.
The administration of sodium bicarbonate, leading to
urinary alkalization, is assumed to prevent hemoglobin-
associated pigment nephropathy. Because fhb is part of
the pathophysiological pathway of pigment nephropathy
[4], we found it predominantly important to determine
the intraoperative concentration of fhb. Because none
of the previously published trials determined the fhbTable 7 Incidence of AKI in the control group and the NaHCO
Surgery type AKIN Control group NaH
Number % Num
CABG AKIN 0 40 48.2 65
AKIN >0 43 51.8 34
Valve AKIN 0 18 58.1 15
AKIN >0 13 41.9 7
CABG + valve AKIN 0 10 43.5 9
AKIN >0 13 56.5 8
Other AKIN 0 16 51.6 23
AKIN >0 15 48.4 13
In the subgroup of coronary artery bypass graft (CABG) surgery patients, the acute
treated with sodium bicarbonate. The median concentrations and IQRs of free hem
Network classification.concentration, our study presents a new and important
perspective by analyzing fhb concentrations, assuming this
to reflect nephrotoxicity in pigment nephropathy. Due to
CPB-induced hemolysis, released fhb causes tubular ob-
struction and tubular cell necrosis. Urinary alkalization by
sodium bicarbonate thus prevents tubular obstruction by
reducing the conversion of hemoglobin to met-hemoglobin
and reducing the endocytotic uptake of hemoglobin, hence
protecting against tubular cell necrosis. Urinary alkalization
protects against oxidant injury by limiting the produc-
tion of free radicals and other reactive species by a pH-
dependent shifting of the equilibrium of the Haber-Weiss
reaction [4,10]. One might presume that in an alkaline mi-
lieu, the physiological scavenging processes of free radicals
are promoted; a direct scavenging ability of bicarbonate
itself has also been suggested [11]. Observing the concen-
tration of fhb revealed a median of 50 mg/dl after ending
CPB, which might represent an optimal interventional
frame. Comparing this concentration range to values re-
ported in the literature shows that (extremely) different
conditions have been reported, ranging from 65 mg/dl
[29]; 54.9 ± 27.1 mg/dl; and 46 ± 25.4 mg/dl after open-
heart CPB surgery (depending on the use of various suc-
tion devices) [30] to 104.4 ± 36.5 mg/dl (patients without
AKI) and 289.0 ± 37.8 mg/dl (patients with AKI) [31] and
120 ± 73 mg/dl during CPB [32]. We observed that3 group according to the surgical procedure
CO3 group Free hemoglobin
ber % P-value Median IQR
65.7 0.0261 43.5 32, 62
34.3
68.2 0.6447 54 37.25, 66.25
31.8
52.9 0.7885 60 49.5, 78.5
47.1
63.9 0.4428 57 42, 78
36.1
kidney injury (AKI) incidence was reduced significantly when patients were
oglobin for each subgroup are also presented. AKIN, Acute Kidney Injury
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in patients with moderate concentrations of fhb (for ex-
ample, patients subjected to CABG surgery only), which
implies that sodium bicarbonate may only protect against
pigment nephropathy to a certain extent. Once fhb rises
to high levels (for example, after a long CPB time, due to
combined valve and CABG surgery), it might exceed the
degree of possible protection afforded by sodium bicar-
bonate. In this regard, other causes of AKI may predomin-
ate over the role of fhb and thereby keep the role of
sodium bicarbonate less efficient.
Because fhb was not observed and analyzed in previ-
ously published studies, it is possible that due to various
surgery conditions the fhb concentrations were consid-
erably higher and thus, not within a frame indicating
that treatment with sodium bicarbonate would still be ef-
fective. Considerably more patients from the trials of
Heringlake, McGuiness and Haase et al. underwent valve
surgery (30, 51 and 48%) with assumed higher concentra-
tions of fhb than were observed in our patient population.
In contrast, we included only 27% of the patients with
valve surgery (valve only and combined with CABG) but
more than 50% of the patients with CABG-only surgery
(versus 38, 29 and 18%, respectively) [13,15,16]. More-
over, we showed that particularly for patients undergoing
CABG surgery, having a lower median concentration of
fhb was associated with experiencing a greater benefit
from treatment with sodium bicarbonate, a finding which
was also just recently shown in a meta-analysis by Bailey
and colleagues [7].
We found a slightly higher median concentration of
fhb in the control group (possibly assuming more harm
due to fhb) and therefore performed a multivariate ana-
lysis with the two factors sodium bicarbonate and fhb,
which demonstrated that the administration of sodium
bicarbonate had an independent, significant preventive
influence on AKI. Consequently, this result highlights
our finding that sodium bicarbonate reduces the inci-
dence of AKI.
Comparing patient outcomes with regard to in-hospital
mortality rates and LOS (hospitalization and intensive
care) revealed no significant differences between patients
who received sodium bicarbonate and those who did not,
although the mortality rate was higher in the NaHCO3
group. Therefore, we cannot support the findings of Haase
et al. [16], who reported significantly increased mortality
in the NaHCO3 group. The other reported trials also did
not find differences in the mortality rate (0 to 4%),
supporting our result of 3% [12-15]. Indeed, in one
trial, a mortality rate of 0% was found in the NaHCO3
group in contrast to 4% in the control group [14]. A signifi-
cantly prolonged duration of treatment in intermediate-
care and high-dependency units in the sodium bicar-
bonate group was observed by Heringlake and colleagues[13], but this finding was not reported elsewhere
[12,14-16].
Considering the positive preventive effect of sodium
bicarbonate, the question arises whether sodium bicar-
bonate also has an effect on the development of chronic
kidney disease. Therefore, we analyzed the serum creatinine
concentration on day 10 after surgery, as one parameter
indicating persisting or chronic kidney disease. Contrary to
our hypothesis, there were no significant differences be-
tween patients classified as AKIN 1, with or without so-
dium bicarbonate treatment. Thus, in our rather small
patient cohort we could not demonstrate a preventive effect
for sodium bicarbonate on the development of chronic kid-
ney disease; future larger trials may analyze this outcome
parameter.
Another difference between the studies can be found
in the administration of sodium bicarbonate; we did not
apply an additional bolus before starting the mainten-
ance dose as in three other trials [12,13,15]. However,
the sodium bicarbonate infusion was started directly
after the induction of anesthesia before beginning sur-
gery, and the patients received a continuous infusion of
sodium bicarbonate until 2 pm on the following day. In
two trials, the infusion was also applied at a constant
rate, beginning with the induction of anesthesia and con-
tinuing for 24 hours, or beginning 1 hour preoperatively
and continuing for only 6 hours after CPB, respectively
[14,16]. The fact that we applied sodium bicarbonate over
a longer time period may have improved the postoperative
conditions, and a bolus-maintenance application may not
be the optimal approach.
We found an AKI incidence close to 45%, although we
not only focused on high-risk patients but also included
all patients with CPB surgery. This choice resulted in the
absence of risk factors for AKI (according to Thakar et al.
[6]) in 18% of the study cohort. Analyzing the effects of
sodium bicarbonate in the low-risk and high-risk patient
cohorts (according to the Thakar score) revealed that in
particular, low-risk patients with fewer than three score
points benefitted from treatment with sodium bicarbon-
ate. In the low-risk cohort, the AKI incidence was only
26% in the NaHCO3 group versus 46% in the control
group (P = 0.01). This distinction may explain why trials
that only included patients at high risk for AKI have
failed to demonstrate any benefit of sodium bicarbonate
therapy [14-16].
Bailey and colleagues suggest that, in contrast to the
low-risk patients, AKI in high-risk patients is not pri-
marily related to CPB time but is closely related to
hemodynamic perturbation [7], indicating a reduced
therapeutic benefit for sodium bicarbonate. Because the
development of CPB-associated AKI is multifactorial,
AKI worsens in tandem with increasing numbers of risk
factors. Thus, the prevention of pigment nephropathy
Wetz et al. Critical Care  (2015) 19:183 Page 9 of 10through the use of sodium bicarbonate, which addresses
only one mechanism of AKI, becomes less effective. Our
findings led to the conclusion that sodium bicarbonate
can be a preventive measure, especially in low-risk AKI
patients and patients undergoing CABG surgery, whereas
it may not avert AKI in high-risk patients.
Conclusion
In this study, we observed that low-risk patients particu-
larly benefited from preventive treatment with sodium bi-
carbonate. In the low-risk cohort (with <3 Thakar points)
and in CABG patients, the AKI incidence was significantly
lower when patients received sodium bicarbonate, whereas
in high-risk patients, the effect on the incidence was not
significant.
Key messages
 Patients with sodium bicarbonate IV infusion
(n = 174) had significantly lower incidence of AKI
than patients without treatment (n = 168): 35.6
versus 50.0%, P = 0.01.
 In the low-risk cohort (with <3 Thakar points;
n = 181), the AKI incidence was significantly lower
(26 versus 46%) when patients received sodium
bicarbonate (P = 0.0113).
 In the high-risk cohort (n = 161), the AKI incidence
was lower in the NaHCO3 group than in the control
group (46 versus 55%), but the difference was not
significant (P = 0.3042).
 The AKI incidence in patients undergoing CABG
surgery was significantly lower in the NaHCO3
group (P = 0.0261). For other types of surgery, the
AKI incidence was decreased, but not significantly.
 The baseline concentration of fhb was 9 mg/dl,
which increased to a median of 50 mg/dl after
ending CPB.
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